Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hsin-Pai Li

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Cancers|July 2, 2021
Combination of Epithelial Growth Factor Receptor Blockers and CDK4/6 Inhibitor for Nasopharyngeal Carcinoma TreatmentHsin-Pai Li, Chen-Yang Huang, Kar-Wai Lui, et al.
Journal of Experimental & Clinical Cancer Research : CR|September 22, 2018
Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinomaCheng-Lung Hsu, Kar-Wai Lui, Lang-Ming Chi, et al.
Cancer Letters|January 22, 2025
Integrated multi-omics analyses of oral squamous cell carcinoma reveal precision patient stratification and personalized treatment strategiesChi-Sheng Wu, Hsin-Pai Li, Chia-Hsun Hsieh, et al.
Nature Communications|September 8, 2017
APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphismTing-Wen Chen, Chi-Ching Lee, Hsuan Liu, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Cancers|July 2, 2021
Combination of Epithelial Growth Factor Receptor Blockers and CDK4/6 Inhibitor for Nasopharyngeal Carcinoma TreatmentHsin-Pai Li, Chen-Yang Huang, Kar-Wai Lui, et al.
Journal of Experimental & Clinical Cancer Research : CR|September 22, 2018
Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinomaCheng-Lung Hsu, Kar-Wai Lui, Lang-Ming Chi, et al.
Cancer Letters|January 22, 2025
Integrated multi-omics analyses of oral squamous cell carcinoma reveal precision patient stratification and personalized treatment strategiesChi-Sheng Wu, Hsin-Pai Li, Chia-Hsun Hsieh, et al.
Nature Communications|September 8, 2017
APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphismTing-Wen Chen, Chi-Ching Lee, Hsuan Liu, et al.
Pageof 4